{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:14:09Z","timestamp":1789578849950,"version":"build-2803163510"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["232A1007512-38"],"award-info":[{"award-number":["232A1007512-38"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006823","name":"Boston Children's Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-025-01081-8","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T11:34:50Z","timestamp":1742211290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["T-ing up the storm: pathogenic cycling lymphocytes in the biology of macrophage activation syndrome"],"prefix":"10.1186","volume":"23","author":[{"given":"Michael T.","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie L.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"issue":"8","key":"1081_CR1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/90609","volume":"2","author":"S Akira","year":"2001","unstructured":"Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2(8):675\u201380.","journal-title":"Nat Immunol"},{"issue":"5","key":"1081_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/emmm.201202382","volume":"5","author":"A Ortega-Gomez","year":"2013","unstructured":"Ortega-Gomez A, Perretti M, Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol Med. 2013;5(5):661\u201374.","journal-title":"EMBO Mol Med"},{"key":"1081_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-med-042921-112837","volume":"74","author":"RQ Cron","year":"2023","unstructured":"Cron RQ, Goyal G, Chatham WW. Cytokine storm syndrome. Annu Rev Med. 2023;74:321\u201337.","journal-title":"Annu Rev Med"},{"key":"1081_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","volume":"13","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari H, Berliner N. Hemophagocytic lymphohistiocytosis. Annu Rev Pathol. 2018;13:27\u201349.","journal-title":"Annu Rev Pathol"},{"key":"1081_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","volume":"10","author":"CB Crayne","year":"2019","unstructured":"Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119.","journal-title":"Front Immunol"},{"issue":"3","key":"1081_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8\u2009+\u2009T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735\u201343.","journal-title":"Blood"},{"issue":"1","key":"1081_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","volume":"76","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, et al. Elevated Circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76(1):166\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"1081_CR8","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood.2020009499","volume":"137","author":"V Chaturvedi","year":"2021","unstructured":"Chaturvedi V, Marsh RA, Zoref-Lorenz A, Owsley E, Chaturvedi V, Nguyen TC, et al. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021;137(17):2337\u201346.","journal-title":"Blood"},{"issue":"3","key":"1081_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1182\/blood.2021013549","volume":"140","author":"A De Matteis","year":"2022","unstructured":"De Matteis A, Colucci M, Rossi MN, Caiello I, Merli P, Tumino N, et al. Expansion of CD4dimCD8\u2009+\u2009T cells characterizes macrophage activation syndrome and other secondary HLH. Blood. 2022;140(3):262\u201373.","journal-title":"Blood"},{"key":"1081_CR10","doi-asserted-by":"crossref","unstructured":"Nguyen TH, Kumar D, Prince C, Martini D, Grunwell JR, Lawrence T et al. Frequency of HLA-DR(+)CD38(hi) T cells identifies and quantifies T-cell activation in hemophagocytic lymphohistiocytosis, hyperinflammation, and immune regulatory disorders. J Allergy Clin Immunol. 2023.","DOI":"10.1016\/j.jaci.2023.07.008"},{"key":"1081_CR11","doi-asserted-by":"crossref","unstructured":"Huang Z, Brodeur KE, Chen L, Du Y, Wobma H, Hsu EE et al. Type I interferon signature and cycling lymphocytes in macrophage activation syndrome. J Clin Invest. 2023.","DOI":"10.1172\/JCI165616"},{"key":"1081_CR12","doi-asserted-by":"crossref","unstructured":"Nigrovic PA. Macrophage Activation Syndrome. Arthritis Rheumatol. 2024.","DOI":"10.1002\/art.43052"},{"issue":"4","key":"1081_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/gene.2012.3","volume":"13","author":"A Ravelli","year":"2012","unstructured":"Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13(4):289\u201398.","journal-title":"Genes Immun"},{"issue":"13","key":"1081_CR14","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","volume":"131","author":"ES Weiss","year":"2018","unstructured":"Weiss ES, Girard-Guyonvarc\u2019h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018;131(13):1442\u201355.","journal-title":"Blood"},{"issue":"2","key":"1081_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2019-216030","volume":"79","author":"PY Lee","year":"2020","unstructured":"Lee PY, Schulert GS, Canna SW, Huang Y, Sundel J, Li Y, et al. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79(2):225\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"1081_CR16","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1182\/blood.2019000936","volume":"135","author":"SW Canna","year":"2020","unstructured":"Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135(16):1332\u201343.","journal-title":"Blood"},{"issue":"5","key":"1081_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259\u201368.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"1081_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124\u201331.","journal-title":"Pediatr Blood Cancer"},{"key":"1081_CR19","unstructured":"Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. Ann Rheum Dis. 2016;75(3):481\u20139. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis:A European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative."},{"key":"1081_CR20","doi-asserted-by":"publisher","first-page":"1190379","DOI":"10.3389\/fimmu.2023.1190379","volume":"14","author":"D Shah","year":"2023","unstructured":"Shah D, Soper B, Shopland L. Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures. Front Immunol. 2023;14:1190379.","journal-title":"Front Immunol"},{"issue":"6","key":"1081_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348.","journal-title":"Nat Med"},{"issue":"4","key":"1081_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"1081_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector Cell-Associated hemophagocytic Lymphohistiocytosis-Like syndrome. Transpl Cell Ther. 2023;29(7):438. e1- e16.","journal-title":"Transpl Cell Ther"},{"key":"1081_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-3-031-59815-9_2","volume":"1448","author":"GE Janka","year":"2024","unstructured":"Janka GE. History of hemophagocytic lymphohistiocytosis. Adv Exp Med Biol. 2024;1448:9\u201319.","journal-title":"Adv Exp Med Biol"},{"issue":"8322","key":"1081_CR25","first-page":"455","volume":"1","author":"RB Scott","year":"1983","unstructured":"Scott RB, Robb-Smith AHT. Histiocytic medullary reticulosis. Lancet. 1983;1(8322):455\u20136.","journal-title":"Lancet"},{"issue":"4","key":"1081_CR26","first-page":"451","volume":"11","author":"JL Stephan","year":"1993","unstructured":"Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol. 1993;11(4):451\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1081_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/00043426-199611000-00002","volume":"18","author":"RM Egeler","year":"1996","unstructured":"Egeler RM, Shapiro R, Loechelt B, Filipovich A. Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 1996;18(4):340\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5446","key":"1081_CR28","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1126\/science.286.5446.1957","volume":"286","author":"SE Stepp","year":"1999","unstructured":"Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in Familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957\u20139.","journal-title":"Science"},{"issue":"12","key":"1081_CR29","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1002\/art.38793","volume":"66","author":"KM Kaufman","year":"2014","unstructured":"Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and Familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2014;66(12):3486\u201395.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"1081_CR30","first-page":"1566","volume":"76","author":"M Correia Marques","year":"2024","unstructured":"Correia Marques M, Rubin D, Shuldiner EG, Datta M, Schmitz E, Gutierrez Cruz G, et al. Enrichment of rare variants of hemophagocytic lymphohistiocytosis genes in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2024;76(10):1566\u201372.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1081_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1084\/jem.20140964","volume":"212","author":"MR Jenkins","year":"2015","unstructured":"Jenkins MR, Rudd-Schmidt JA, Lopez JA, Ramsbottom KM, Mannering SI, Andrews DM, et al. Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015;212(3):307\u201317.","journal-title":"J Exp Med"},{"issue":"8","key":"1081_CR32","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00277-017-2993-y","volume":"96","author":"M Lin","year":"2017","unstructured":"Lin M, Park S, Hayden A, Giustini D, Trinkaus M, Pudek M, et al. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann Hematol. 2017;96(8):1241\u201351.","journal-title":"Ann Hematol"},{"issue":"1","key":"1081_CR33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jaci.2015.12.1314","volume":"138","author":"S Humblet-Baron","year":"2016","unstructured":"Humblet-Baron S, Franckaert D, Dooley J, Bornschein S, Cauwe B, Schonefeldt S, et al. IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2016;138(1):200\u20139. e8.","journal-title":"J Allergy Clin Immunol"},{"issue":"26","key":"1081_CR34","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1182\/blood-2013-04-495309","volume":"121","author":"CE Terrell","year":"2013","unstructured":"Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells. Blood. 2013;121(26):5184\u201391.","journal-title":"Blood"},{"issue":"10","key":"1081_CR35","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/ng.3089","volume":"46","author":"SW Canna","year":"2014","unstructured":"Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140\u20136.","journal-title":"Nat Genet"},{"issue":"10","key":"1081_CR36","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ng.3066","volume":"46","author":"N Romberg","year":"2014","unstructured":"Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M, et al. Mutation of NLRC4 causes a syndrome of Enterocolitis and autoinflammation. Nat Genet. 2014;46(10):1135\u20139.","journal-title":"Nat Genet"},{"issue":"12","key":"1081_CR37","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1084\/jem.20190147","volume":"216","author":"MT Lam","year":"2019","unstructured":"Lam MT, Coppola S, Krumbach OHF, Prencipe G, Insalaco A, Cifaldi C, et al. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J Exp Med. 2019;216(12):2778\u201399.","journal-title":"J Exp Med"},{"issue":"1","key":"1081_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2018-05-845818","volume":"132","author":"B Tesi","year":"2018","unstructured":"Tesi B, Bryceson YT. HLH: genomics illuminates pathophysiological diversity. Blood. 2018;132(1):5\u20137.","journal-title":"Blood"},{"key":"1081_CR39","doi-asserted-by":"publisher","first-page":"867753","DOI":"10.3389\/fimmu.2022.867753","volume":"13","author":"P Vignesh","year":"2022","unstructured":"Vignesh P, Anjani G, Kumrah R, Singh A, Mondal S, Nameirakpam J, et al. Features of hemophagocytic lymphohistiocytosis in infants with severe combined immunodeficiency: our experience from Chandigarh, North India. Front Immunol. 2022;13:867753.","journal-title":"Front Immunol"},{"issue":"6","key":"1081_CR40","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.jaci.2014.11.030","volume":"135","author":"B Tesi","year":"2015","unstructured":"Tesi B, Sieni E, Neves C, Romano F, Cetica V, Cordeiro AI, et al. Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-gamma receptor deficiency. J Allergy Clin Immunol. 2015;135(6):1638\u201341.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1081_CR41","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.jaci.2018.10.068","volume":"143","author":"S Humblet-Baron","year":"2019","unstructured":"Humblet-Baron S, Franckaert D, Dooley J, Ailal F, Bousfiha A, Deswarte C, et al. IFN-gamma and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2019;143(6):2215\u201326. e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1081_CR42","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/art.37958","volume":"65","author":"SW Canna","year":"2013","unstructured":"Canna SW, Wrobel J, Chu N, Kreiger PA, Paessler M, Behrens EM. Interferon-gamma mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum. 2013;65(7):1764\u201375.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1081_CR43","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1172\/JCI43157","volume":"121","author":"EM Behrens","year":"2011","unstructured":"Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011;121(6):2264\u201377.","journal-title":"J Clin Invest"},{"key":"1081_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/978-3-031-59815-9_10","volume":"1448","author":"T Sekine","year":"2024","unstructured":"Sekine T, Galgano D, Casoni GP, Meeths M, Cron RQ, Bryceson YT. CD8(+) T cell biology in cytokine storm syndromes. Adv Exp Med Biol. 2024;1448:129\u201344.","journal-title":"Adv Exp Med Biol"},{"key":"1081_CR45","doi-asserted-by":"publisher","first-page":"1286749","DOI":"10.3389\/fimmu.2023.1286749","volume":"14","author":"S Raimbault","year":"2023","unstructured":"Raimbault S, Monneret G, Gossez M, Venet F, Belot A, Zekre F, et al. Elevated monocyte HLA-DR in pediatric secondary hemophagocytic lymphohistiocytosis: a retrospective study. Front Immunol. 2023;14:1286749.","journal-title":"Front Immunol"},{"issue":"1","key":"1081_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13054-018-2146-2","volume":"22","author":"S Remy","year":"2018","unstructured":"Remy S, Gossez M, Belot A, Hayman J, Portefaix A, Venet F, et al. Massive increase in monocyte HLA-DR expression can be used to discriminate between septic shock and hemophagocytic lymphohistiocytosis-induced shock. Crit Care. 2018;22(1):213.","journal-title":"Crit Care"},{"key":"1081_CR47","doi-asserted-by":"publisher","first-page":"597959","DOI":"10.3389\/fimmu.2020.597959","volume":"11","author":"ZL Piedra-Quintero","year":"2020","unstructured":"Piedra-Quintero ZL, Wilson Z, Nava P, Guerau-de-Arellano M. CD38: an Immunomodulatory molecule in inflammation and autoimmunity. Front Immunol. 2020;11:597959.","journal-title":"Front Immunol"},{"issue":"1","key":"1081_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0008-8749(88)90073-1","volume":"117","author":"B Gansbacher","year":"1988","unstructured":"Gansbacher B, Zier KS. Regulation of HLA-DR, DP, and DQ expression in activated T cells. Cell Immunol. 1988;117(1):22\u201334.","journal-title":"Cell Immunol"},{"issue":"3","key":"1081_CR49","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.immuni.2020.07.009","volume":"53","author":"L Zhu","year":"2020","unstructured":"Zhu L, Yang P, Zhao Y, Zhuang Z, Wang Z, Song R, et al. Single-Cell sequencing of peripheral mononuclear cells reveals distinct immune response landscapes of COVID-19 and influenza patients. Immunity. 2020;53(3):685\u201396. e3.","journal-title":"Immunity"},{"issue":"11","key":"1081_CR50","doi-asserted-by":"publisher","first-page":"e2451140","DOI":"10.1002\/eji.202451140","volume":"54","author":"L Lodi","year":"2024","unstructured":"Lodi L, Sarli WM, Ricci S, Pisano L, Boscia S, Mastrolia MV, et al. CD38(high)\/HLA-DR(+)CD8(+) T lymphocytes display pathogen-specific expansion regardless of hemophagocytic lymphohistiocytosis. Eur J Immunol. 2024;54(11):e2451140.","journal-title":"Eur J Immunol"},{"key":"1081_CR51","doi-asserted-by":"crossref","unstructured":"Liu M, Brodeur KE, Bledsoe JR, Harris CN, Joerger J, Weng R et al. Features of hyperinflammation link the biology of EBV infection and cytokine storm syndromes. J Allergy Clin Immunol. 2024.","DOI":"10.1016\/j.jaci.2024.11.029"},{"key":"1081_CR52","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fimmu.2013.00156","volume":"4","author":"PE Kima","year":"2013","unstructured":"Kima PE, Soong L. Interferon gamma in leishmaniasis. Front Immunol. 2013;4:156.","journal-title":"Front Immunol"},{"issue":"1","key":"1081_CR53","doi-asserted-by":"publisher","first-page":"e85422","DOI":"10.1371\/journal.pone.0085422","volume":"9","author":"SK Dunmire","year":"2014","unstructured":"Dunmire SK, Odumade OA, Porter JL, Reyes-Genere J, Schmeling DO, Bilgic H, et al. Primary EBV infection induces an expression profile distinct from other viruses but similar to hemophagocytic syndromes. PLoS ONE. 2014;9(1):e85422.","journal-title":"PLoS ONE"},{"issue":"1","key":"1081_CR54","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41467-018-03243-7","volume":"9","author":"Z Wang","year":"2018","unstructured":"Wang Z, Zhu L, Nguyen THO, Wan Y, Sant S, Quinones-Parra SM, et al. Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells persist during fatal H7N9 disease. Nat Commun. 2018;9(1):824.","journal-title":"Nat Commun"},{"issue":"7","key":"1081_CR55","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/infdis\/jiv550","volume":"213","author":"GS Schulert","year":"2016","unstructured":"Schulert GS, Zhang M, Fall N, Husami A, Kissell D, Hanosh A, et al. Whole-Exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. J Infect Dis. 2016;213(7):1180\u20138.","journal-title":"J Infect Dis"},{"issue":"1","key":"1081_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40272-019-00367-1","volume":"22","author":"LA Henderson","year":"2020","unstructured":"Henderson LA, Cron RQ. Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management. Paediatr Drugs. 2020;22(1):29\u201344.","journal-title":"Paediatr Drugs"},{"key":"1081_CR57","unstructured":"Baldo F, Erkens RGA, Mizuta M, Rogani G, Lucioni F, Bracaglia C et al. Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project. Rheumatology (Oxford). 2024."},{"key":"1081_CR58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12969-015-0055-3","volume":"13","author":"V Boom","year":"2015","unstructured":"Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat NM, et al. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2015;13:55.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"19","key":"1081_CR59","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"1081_CR60","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82(6):857\u201365.","journal-title":"Ann Rheum Dis"},{"key":"1081_CR61","doi-asserted-by":"crossref","unstructured":"Chandrakasan S, Allen CE, Bhatla D, Carter J, Chien M, Cooper R et al. Emapalumab treatment in patients with rheumatologic Disease-Associated hemophagocytic lymphohistiocytosis in the united States: A retrospective medical chart review study. Arthritis Rheumatol. 2024.","DOI":"10.1002\/art.42985"},{"issue":"9","key":"1081_CR62","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1182\/bloodadvances.2023012217","volume":"8","author":"S Chandrakasan","year":"2024","unstructured":"Chandrakasan S, Jordan MB, Baker A, Behrens EM, Bhatla D, Chien M, et al. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Blood Adv. 2024;8(9):2248\u201358.","journal-title":"Blood Adv"},{"issue":"3","key":"1081_CR63","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2022.12.816","volume":"151","author":"Y Du","year":"2023","unstructured":"Du Y, Liu M, Nigrovic PA, Dedeoglu F, Lee PY. Biologics and JAK inhibitors for the treatment of Monogenic systemic autoinflammatory diseases in children. J Allergy Clin Immunol. 2023;151(3):607\u201318.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1081_CR64","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/ejh.13593","volume":"106","author":"S Hansen","year":"2021","unstructured":"Hansen S, Alduaij W, Biggs CM, Belga S, Luecke K, Merkeley H, et al. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series. Eur J Haematol. 2021;106(5):654\u201361.","journal-title":"Eur J Haematol"},{"key":"1081_CR65","doi-asserted-by":"crossref","unstructured":"Irabu H, Kaneko S, Miyaoka F, Tomomasa D, Shimbo A, Nishimura A et al. Yang and Ying of ruxolitinib administration for macrophage activation syndrome complicated by systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2024.","DOI":"10.1093\/rheumatology\/keae656"},{"issue":"12","key":"1081_CR66","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1136\/ard-2024-226433","volume":"83","author":"Z Song","year":"2024","unstructured":"Song Z, Yao H, Jin Y, Li X, Jia Y, He J, et al. Ruxolitinib as a salvage therapy in adult-onset macrophage activation syndrome: insights from eight cases. Ann Rheum Dis. 2024;83(12):1798\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"1081_CR67","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood.2021014860","volume":"139","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zhao YZ, Ma HH, Wang D, Cui L, Li WJ, et al. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis. Blood. 2022;139(24):3493\u2013504.","journal-title":"Blood"},{"issue":"1","key":"1081_CR68","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4049\/jimmunol.1302282","volume":"192","author":"TS Johnson","year":"2014","unstructured":"Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol. 2014;192(1):84\u201391.","journal-title":"J Immunol"},{"issue":"5","key":"1081_CR69","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","volume":"6","author":"S Ehl","year":"2018","unstructured":"Ehl S, Astigarraga I, von Bahr Greenwood T, Hines M, Horne A, Ishii E, et al. Recommendations for the use of Etoposide-Based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH steering committee of the histiocyte society. J Allergy Clin Immunol Pract. 2018;6(5):1508\u201317.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"1081_CR70","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3899\/jrheum.200941","volume":"48","author":"A Horne","year":"2021","unstructured":"Horne A, von Bahr Greenwood T, Chiang SCC, Meeths M, Bjorklund C, Ekelund M, et al. Efficacy of moderately dosed Etoposide in macrophage activation Syndrome-Hemophagocytic lymphohistiocytosis. J Rheumatol. 2021;48(10):1596\u2013602.","journal-title":"J Rheumatol"},{"issue":"2","key":"1081_CR71","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274\u201393.","journal-title":"Cell"},{"issue":"10","key":"1081_CR72","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri3901","volume":"15","author":"T Weichhart","year":"2015","unstructured":"Weichhart T, Hengstschlager M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15(10):599\u2013614.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1081_CR73","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1038\/s41467-022-34480-6","volume":"13","author":"Z Huang","year":"2022","unstructured":"Huang Z, You X, Chen L, Du Y, Brodeur K, Jee H, et al. mTORC1 links pathology in experimental models of still\u2019s disease and macrophage activation syndrome. Nat Commun. 2022;13(1):6915.","journal-title":"Nat Commun"},{"issue":"7","key":"1081_CR74","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/pbc.23226","volume":"57","author":"JA Rothman","year":"2011","unstructured":"Rothman JA, Das R, Teachey DT, Paessler ME, Nichols KE. Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice. Pediatr Blood Cancer. 2011;57(7):1239\u201343.","journal-title":"Pediatr Blood Cancer"},{"key":"1081_CR75","doi-asserted-by":"crossref","unstructured":"Cam V, Sag E, Bilginer Y, Ozen S. A case with systemic juvenile idiopathic arthritis treated with tofacitinib and rapamycin. Rheumatology (Oxford). 2024.","DOI":"10.1093\/rheumatology\/keae637"},{"issue":"7","key":"1081_CR76","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1093\/rheumatology\/keab114","volume":"60","author":"S Concha","year":"2021","unstructured":"Concha S, Rey-Jurado E, Poli MC, Hoyos-Bachiloglu R, Borzutzky A. Refractory systemic juvenile idiopathic arthritis successfully treated with Rapamycin. Rheumatology (Oxford). 2021;60(7):e250\u20131.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1081_CR77","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13\u201329.","journal-title":"Blood"},{"issue":"10","key":"1081_CR78","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","volume":"25","author":"L Moreno","year":"2019","unstructured":"Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, et al. The mechanism of action of the Anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176\u201387.","journal-title":"Clin Cancer Res"},{"issue":"27","key":"1081_CR79","doi-asserted-by":"publisher","first-page":"e2207394","DOI":"10.1002\/advs.202207394","volume":"10","author":"C Liao","year":"2023","unstructured":"Liao C, Wang Y, Huang Y, Duan Y, Liang Y, Chen J, et al. CD38-Specific CAR integrated into CD38 locus driven by different promoters causes distinct antitumor activities of T and NK cells. Adv Sci (Weinh). 2023;10(27):e2207394.","journal-title":"Adv Sci (Weinh)"},{"issue":"12","key":"1081_CR80","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1084\/jem.20020369","volume":"195","author":"TC Becker","year":"2002","unstructured":"Becker TC, Wherry EJ, Boone D, Murali-Krishna K, Antia R, Ma A, et al. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med. 2002;195(12):1541\u20138.","journal-title":"J Exp Med"},{"issue":"1","key":"1081_CR81","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-065X.2008.00737.x","volume":"227","author":"O Takeuchi","year":"2009","unstructured":"Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009;227(1):75\u201386.","journal-title":"Immunol Rev"},{"key":"1081_CR82","doi-asserted-by":"crossref","unstructured":"Verweyen EL, Thakkar K, Dhakal S, Baker E, Chetal K, Schnell D et al. Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. J Clin Invest. 2023;133(22).","DOI":"10.1172\/JCI166741"},{"issue":"3","key":"1081_CR83","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"9","key":"1081_CR84","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/art.21249","volume":"52","author":"B Baslund","year":"2005","unstructured":"Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 2005;52(9):2686\u201392.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1081_CR85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","volume":"20","author":"E Landy","year":"2024","unstructured":"Landy E, Carol H, Ring A, Canna S. Biological and clinical roles of IL-18 in inflammatory diseases. Nat Rev Rheumatol. 2024;20(1):33\u201347.","journal-title":"Nat Rev Rheumatol"},{"key":"1081_CR86","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molimm.2017.06.025","volume":"88","author":"E Lusty","year":"2017","unstructured":"Lusty E, Poznanski SM, Kwofie K, Mandur TS, Lee DA, Richards CD, et al. IL-18\/IL-15\/IL-12 synergy induces elevated and prolonged IFN-gamma production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation. Mol Immunol. 2017;88:138\u201347.","journal-title":"Mol Immunol"},{"issue":"7","key":"1081_CR87","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1002\/1521-4141(200107)31:7<2236::AID-IMMU2236>3.0.CO;2-G","volume":"31","author":"S Matikainen","year":"2001","unstructured":"Matikainen S, Paananen A, Miettinen M, Kurimoto M, Timonen T, Julkunen I, et al. IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur J Immunol. 2001;31(7):2236\u201345.","journal-title":"Eur J Immunol"},{"key":"1081_CR88","doi-asserted-by":"crossref","unstructured":"Caorsi R, Bertoni A, Matucci-Cerinic C, Natoli V, Palmeri S, Rosina S et al. Long-term efficacy of MAS825, a bispecific anti-IL1beta and IL-18 monoclonal antibody, in two patients with sJIA and recurrent episodes of MAS. Rheumatology (Oxford). 2024.","DOI":"10.1093\/rheumatology\/keae440"},{"issue":"2","key":"1081_CR89","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/rheumatology\/kez284","volume":"59","author":"S Yasin","year":"2020","unstructured":"Yasin S, Solomon K, Canna SW, Girard-Guyonvarc\u2019h C, Gabay C, Schiffrin E, et al. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatology (Oxford). 2020;59(2):442\u20135.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01081-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01081-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01081-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T11:34:57Z","timestamp":1742211297000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-025-01081-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1081"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01081-8","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}